Efficacy of Nalmefene in Patients With Alcohol Dependence (ESENSE2)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00812461 |
|
Recruitment Status :
Completed
First Posted : December 22, 2008
Results First Posted : July 9, 2013
Last Update Posted : July 22, 2013
|
Sponsor:
H. Lundbeck A/S
Information provided by (Responsible Party):
H. Lundbeck A/S
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
The purpose of the study is to evaluate the efficacy, safety and tolerability of nalmefene in the treatment of alcohol dependence.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Alcohol Dependence | Drug: Placebo Drug: Nalmefene | Phase 3 |
Alcohol dependence is a maladaptive pattern of alcohol use, leading to clinically significant impairment or distress, as manifested by at least three of a number of criteria such as tolerance, withdrawal symptoms, frequent use of alcohol in larger amounts or over longer periods than was intended, and others. Excessive intake of alcohol reduces the life span by a decade, and alcohol drinking is strongly related to mortality from liver cirrhosis, chronic pancreatitis, certain cancers, hypertension, accidents and violence. This study is planned to evaluate the efficacy and safety of as needed use of nalmefene 18.06 mg versus placebo in decreasing monthly Heavy Drinking Days (HDDs) and decreasing the total consumption during a period of 24 weeks in adult patients with alcohol dependence.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 678 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Double (Participant, Investigator) |
| Primary Purpose: | Treatment |
| Official Title: | Nalmefene Efficacy Study II: Randomised, Double-blind, Placebo-controlled, Parallel-group, Efficacy Study of 20 mg Nalmefene, as Needed Use, in Patients With Alcohol Dependence |
| Study Start Date : | March 2009 |
| Actual Primary Completion Date : | March 2011 |
| Actual Study Completion Date : | April 2011 |
Resource links provided by the National Library of Medicine
MedlinePlus related topics:
Alcohol Use Disorder (AUD)
| Arm | Intervention/treatment |
|---|---|
| Placebo Comparator: Placebo |
Drug: Placebo
as-needed use, tablets, orally, 6 months |
| Experimental: Nalmefene |
Drug: Nalmefene
18.06 mg, as-needed use, tablets, orally, 6 months. 18.06 mg nalmefene equals 20 mg nalmefene hydrochloride.
Other Name: Selincro™ |
Primary Outcome Measures :
- Change From Baseline in the Monthly Number of Heavy Drinking Days (HDDs) [ Time Frame: Baseline and Month 6 ]Number of HDDs over a month (28 days), where one HDD was defined as a day with alcohol consumption ≥60 grams (g) for men and ≥40 g for women.
- Change From Baseline in the Monthly Total Alcohol Consumption (TAC) [ Time Frame: Baseline and Month 6 ]TAC was defined as mean daily alcohol consumption in g/day over a month (28 days).
Secondary Outcome Measures :
- Drinking Risk Level (RSDRL) Response [ Time Frame: Month 6 ]RSDRL response was defined as a downward shift from baseline in Drinking Risk Level (DRL); for patients at very high risk at Baseline: a shift to medium risk or below, and for patients at high or medium risk at Baseline: a shift to low risk or below.
- Change From Baseline in Clinical Status Using CGI-S [ Time Frame: Baseline and Week 24 ]The Clinical Global Impression - Severity of Illness (CGI-S) provides the clinician's impression of the patient's current state of mental illness. The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (Normal - not at all ill) to 7 (among the most extremely ill patients).
- Change in Clinical Status Using the CGI-I [ Time Frame: Week 24 ]The Clinical Global Impression - Global Improvement (CGI-I) provides the clinician's impression of the patient's improvement (or worsening). The clinician assesses the patient's condition relative to a baseline on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse).
- Liver Function Test Gamma-glutamyl Transferase (GGT) [ Time Frame: Week 24 ]GGT values
- Liver Function Test Alanine Aminotransferase (ALAT) [ Time Frame: Week 24 ]ALAT values
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
In- and outpatients who:
- had a primary diagnosis of alcohol dependence according to Diagnostic and Statistical Manual of Mental Disorders - text revision (DSM-IV-TR) criteria
- had had ≥6 HDDs in the 4 weeks preceding the Screening Visit
- had had an average alcohol consumption at WHO medium risk level or above in the 4 weeks preceding the Screening Visit
Exclusion Criteria:
The patient:
- had a DSM-IV Axis I disorder other than alcohol dependence or nicotine dependence
- had an antisocial personality disorder
- had risk of suicide evaluated by the suicidality module of the Mini-International Neuropsychiatric Interview (MINI)
- had a history of delirium tremens or alcohol withdrawal seizures
- reported current or recent (within 3 months preceding screening) treatment with disulfiram, acamprosate, topiramate, naltrexone or carbimide, or with any opioid antagonists
- reported current or recent treatment with antipsychotics or antidepressants
- was pregnant or breast-feeding
Other protocol-defined inclusion and exclusion criteria may apply.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00812461
Locations
Show 57 study locations
Sponsors and Collaborators
H. Lundbeck A/S
Investigators
| Study Director: | Email contact via H. Lundbeck A/S | LundbeckClinicalTrials@lundbeck.com |
Publications of Results:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | H. Lundbeck A/S |
| ClinicalTrials.gov Identifier: | NCT00812461 |
| Other Study ID Numbers: |
12023A 2007-002563-27 ( EudraCT Number ) |
| First Posted: | December 22, 2008 Key Record Dates |
| Results First Posted: | July 9, 2013 |
| Last Update Posted: | July 22, 2013 |
| Last Verified: | July 2013 |
Keywords provided by H. Lundbeck A/S:
|
Pharmacologic Actions Alcohol-Related Disorders Alcoholism Mental Disorders Central Nervous System Agents |
Additional relevant MeSH terms:
|
Alcoholism Alcohol-Related Disorders Substance-Related Disorders Chemically-Induced Disorders Mental Disorders |
Nalmefene Narcotic Antagonists Physiological Effects of Drugs Sensory System Agents Peripheral Nervous System Agents |